Bavarian Nordic Appoints James B. Breitmeyer As Executive Vice President And Divison President Of Its Cancer Vaccine Division
KVISTGAARD, Denmark, Feb. 8, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) announced today that it has appointed James B. Breitmeyer, M.D., Ph.D. to the position of Executive Vice President and Division President of its Cancer Vaccine division.
"We are pleased to welcome Dr. Breitmeyer to our executive management team," commented Anders Hedegaard, President and CEO of Bavarian Nordic. "We believe that his long executive career in the pharmaceutical industry combined with his solid oncology expertise will provide the perfect leadership for our cancer vaccine division. He will apply more than two decades of clinical development experience from research through commercialization to the advancement of our cancer immunotherapy candidates, in particular PROSTVAC(R), which is currently in Phase 3 development."
"I am very enthusiastic about joining Bavarian Nordic at this exciting time," said James B. Breitmeyer, M.D., Ph.D. "Immunotherapy of cancer is a career-long interest of mine, and I believe PROSTVAC(R) represents a state-of-the art approach, and a potentially improved treatment for patients suffering from advanced prostate cancer. I am looking forward to leading the development of this promising product candidate successfully through Phase 3 on its path towards commercialization."Dr. Breitmeyer served as Executive Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals Inc. from 2006 to 2012. From 2001 to 2006, he served as Chief Medical Officer of Applied Molecular Evolution Inc., a wholly-owned subsidiary of Eli Lilly and Co. From 2000 to 2001, Dr. Breitmeyer served as President and Chief Executive Officer of the Harvard Clinical Research Institute. From 1991 to 2000, he held a variety of positions at Serono Laboratories Inc., including Chief Medical Officer and Senior Vice President of Research and Development. Prior to Serono, he served as a scientific advisor to Immunogen Inc., and held clinical and teaching positions at the Dana Farber Cancer Institute and Harvard Medical School.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV